AU Patent

AU2019384963B2 — Methods of treating Rett syndrome using fenfluramine

Assigned to Zogenix International Ltd · Expires 2022-05-26 · 4y expired

What this patent protects

A method of treating and/or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HT

USPTO Abstract

A method of treating and/or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HT

Drugs covered by this patent

Patent Metadata

Patent number
AU2019384963B2
Jurisdiction
AU
Classification
—
Expires
2022-05-26
Drug substance claim
No
Drug product claim
No
Assignee
Zogenix International Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.